Key result
Ficus elastica subfraction inhibits HMG-CoA reductase and improves lipid profiles comparably to simvastatin in rats.
Why the study?
Do Ficus elastica phytochemicals improve lipid parameters, oxidative homeostasis, and aortic histology in high-fat diet-induced hyperlipidemic rats?
Do Ficus elastica phytochemicals improve lipid parameters, oxidative homeostasis, and aortic histology in high-fat diet-induced hyperlipidemic rats?
Ficus elastica phytochemicals demonstrate preclinical antihyperlipidemic and antioxidant effects comparable to simvastatin in hyperlipidemic rats, alongside preservation of aortic tissue architecture.
Background and purpose: Hyperlipidemia remains a major cardiovascular risk factor requiring novel therapeutic strategies beyond conventional statin therapy. This study investigated the antihyperlipidemic and antioxidant properties of Ficus elastica Roxb. ex Hornem. (Moraceae) phytochemicals through integrated in vitro, in vivo , and in silico approaches. Experimental approach: Eight chromatographic subfractions were screened for 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity. Lipid profile, lipid peroxidation, and histopathology were evaluated in rats fed a high-fat diet to induce hyperlipidemia. Chemical composition was characterized using liquid chromatography high-resolution mass spectrometry (LC-HRMS) and subsequently investigated through molecular docking simulations. Findings/Results: Subfraction 4 demonstrated the strongest HMG-CoA reductase inhibitory activity. In vivo evaluation in high-fat diet-induced hyperlipidemic rats revealed dose-dependent improvements in all lipid parameters, with effects statistically comparable to simvastatin. Subfraction 4 additionally reduced serum malondialdehyde to levels statistically indistinguishable from normal controls, indicating restoration of oxidative homeostasis. Histological preservation of aortic endothelial integrity and elastic fiber organization was associated with reduced intima-media thickness, suggesting attenuation of early atherosclerotic changes. LC-HRMS analysis tentatively identified four major constituents, including phlorin, clausarinol, ginsenoyne C, and piptolinic acid A. Molecular docking analysis suggested that clausarinol and ginsenoyne C exhibited comparatively higher predicted binding affinity than simvastatin toward PCSK9 and PPAR-α, respectively. Conclusion and implications: These findings support the potential of F. elastica phytochemicals as candidates for hyperlipidemia management.
No takes yet. Share an insight, caveat, or question.
Susanti et al. (2026) studied Hyperlipidemia. Ficus elastica phytochemicals (Subfraction 4) vs. Simvastatin and normal controls was evaluated on HMG-CoA reductase inhibitory activity, lipid profile, serum malondialdehyde, and aortic histopathology. Ficus elastica subfraction 4 showed the strongest HMG-CoA reductase inhibition among 8 subfractions and improved lipid profiles in hyperlipidemic rats comparably to simvastatin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: